September 24, 2017 12:40 PM ET

Biotechnology

Company Overview of Eleven Biotherapeutics, Inc.

Company Overview

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company’s lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. It is also developing systemically-administered TPTs, including VB6-845d for the treatment of multiple types of epithelial cell adhesion molecule positive solid tumors. Eleven Bio...

245 First Street

Suite 1800

Cambridge, MA 02142

United States

Founded in 2008

34 Employees

Phone:

617-444-8550

Key Executives for Eleven Biotherapeutics, Inc.

Chief Executive Officer, President and Director
Age: 49
Total Annual Compensation: $119.1K
Chief Financial Officer and Treasurer
Age: 49
Total Annual Compensation: $380.0K
Chief Medical Officer
Age: 61
Total Annual Compensation: $116.9K
Compensation as of Fiscal Year 2016.

Eleven Biotherapeutics, Inc. Key Developments

Eleven Biotherapeutics, Inc. Announces Resignation of Arthur Decillis as Chief Medical Officer, Effective as of October 3, 2017

On September 19, 2017, Arthur DeCillis, M.D. announced that, while he will continue to provide senior advice and guidance to Eleven Biotherapeutics regarding its clinical trials, he will do so in a consulting and advisory role. In connection with this transition, on September 19, 2017, Mr. DeCillis resigned his position as Chief Medical Officer effective as of October 3, 2017.

Eleven Biotherapeutics, Inc. Announces Completion of Vicinium Manufacturing for Ongoing Clinical Trials in Non-Muscle Invasive Bladder Cancer

Eleven Biotherapeutics, Inc. announced that it has completed the manufacturing of all Vicinium necessary for its ongoing Phase 3 registration trial in patients with non-muscle invasive bladder cancer (NMIBC), and for its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. In conjunction with this achievement, Eleven is ending its large-scale manufacturing activities and redirecting resources toward completing its Phase 3 trial and preparing for discussions with the U.S. Food and Drug Administration (FDA) regarding, as appropriate, the submission of a Biologics License Application (BLA) for Vicinium in patients with NMIBC. This change will include a reduction of headcount and associated cost savings. For commercialization, the Company plans to engage an external, Current Good Manufacturing Practice (cGMP) compliant, contract manufacturer. Vicinium is manufactured as a single protein anti-epithelial cell adhesion molecule (anti-EpCAM) fusion protein fused with Pseudomonas Exotoxin A (ETA) designed to specifically target and deliver a potent anti-cancer payload directly into tumor cells. It is constructed with a stable, genetically-engineered linker to ensure its potent protein payload remains attached until it is internalized by the cancer cell, which is believed to decrease the risk of toxicity to healthy tissues thereby improving the compound’s safety. Vicinium’s one-step manufacturing process offers significant cost advantages and results in the production of a homogenous product, with less batch-to-batch variability than most antibody drug conjugates. Vicinium is currently in a Phase 3 registration clinical trial for the treatment of high-grade non-muscle invasive bladder cancer (NMIBC) in patients who have previously received two courses of Bacillus Calmette-Guérin (BCG) and whose disease is now BCG-unresponsive. Eleven Biotherapeutics intends to enroll 134 subjects in the trial, including 77 subjects with carcinoma in situ (CIS), at over 70 centers in the United States and Canada. Primary and secondary endpoints include complete response (CR) in CIS subjects, time to disease recurrence and event free survival. The company expects to complete patient enrollment in the first quarter of 2018 and to report topline three-month data in mid-2018.

Eleven Biotherapeutics, Inc. Presents at Rodman & Renshaw 19th Annual Global Investment Conference, Sep-11-2017 03:00 PM

Eleven Biotherapeutics, Inc. Presents at Rodman & Renshaw 19th Annual Global Investment Conference, Sep-11-2017 03:00 PM. Venue: Lotte New York Palace Hotel, 55 Madison Ave, New York, New York, United States. Speakers: Stephen A. Hurly, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Eleven Biotherapeutics, Inc., please visit www.elevenbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.